IMPORTANT SAFETY INFORMATION

• Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.

• You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.

• EUFLEXXA has not been tested in pregnant women, women who are nursing or children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).

• The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see enclosed Full Prescribing Information in pocket.

INDICATION

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

WHAT TO EXPECT AFTER YOUR EUFLEXXA INJECTIONS

• Some people experience moderate pain relief after the 1st or 2nd injection of EUFLEXXA.

• Most people experience significant relief after the 3rd (last) injection.

• For maximum pain relief, be sure to get all 3 injections.

• When it comes to duration of pain relief, each person is different. In general, 1 course of 3 EUFLEXXA injections has been shown to provide up to 6 months of knee pain relief.

• The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see Important Safety Information on back cover and Full Prescribing Information in pocket.

SCHEDULE ALL 3 INJECTIONS TODAY!

1 2 3

date: time: date: time: date: time:

IMPORTANT SAFETY INFORMATION

• Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.

• You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.

• EUFLEXXA has not been tested in pregnant women, women who are nursing or children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).

• The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see enclosed Full Prescribing Information in pocket.
What should I do after receiving a EUFLEXXA injection?

- Avoid physical activity for 48 hours after receiving your EUFLEXXA injection to keep your knee from swelling.
- Ice your knee if you have any mild pain or swelling near the injection site.
- Avoid standing on your feet for more than 1 hour at a time during the first 48 hours following the injection.
- Ask your healthcare provider when you should begin major physical activities again.
- Call your doctor immediately if you experience joint pain, back pain, limb/muscle pain, joint swelling, or any other problems.
What should I expect from treatment with EUFLEXXA?

- Some people experience moderate pain relief after the 1st or 2nd injection of EUFLEXXA.
- Most people experience significant relief after the 3rd (last) injection.
- For maximum pain relief, be sure to get all 3 injections.
- When it comes to duration of pain relief, each person is different. In general, 1 course of 3 EUFLEXXA injections has been shown to provide up to 6 months of knee pain relief.2
- The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see Important Safety Information on back cover and Full Prescribing Information in pocket.

SCHEDULE ALL 3 INJECTIONS TODAY!

1. Date: 
   Time: 

2. Date: 
   Time: 

3. Date: 
   Time: 

IMPORTANT SAFETY INFORMATION

- Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
- You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
- EUFLEXXA has not been tested in pregnant women, women who are nursing or children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
- The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see Important Safety Information on back cover and Full Prescribing Information in pocket.
IMPORTANT SAFETY INFORMATION

• Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.

• You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.

• EUFLEXXA has not been tested in pregnant women, women who are nursing or children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).

• The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see enclosed Full Prescribing Information in pocket.

INDICATION

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy. EUFLEXXA may only be injected into the knee, performed by a doctor or other qualified healthcare professional.

WHAT TO EXPECT AFTER YOUR EUFLEXXA INJECTIONS

• Some people experience moderate pain relief after the 1st or 2nd injection of EUFLEXXA.
• Most people experience significant relief after the 3rd (last) injection.
• For maximum pain relief, be sure to get all 3 injections.
• When it comes to duration of pain relief, each person is different. In general, 1 course of 3 EUFLEXXA injections has been shown to provide up to 6 months of knee pain relief.
• The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see Important Safety Information on back cover and Full Prescribing Information in pocket.
Arthralgia • Back pain • Pain in extremity

Adverse event information regarding the use of EUFLEXXA as a treatment for pain in OA of the knee was

Use in Specific Populations

Do not use after expiration date.

Safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other

CONTRAINDICATIONS

in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple

INDICATION

randomized into groups of equal size to receive either EUFLEXXA (n=160) or the active control (n=161).

available hyaluronan product) study conducted at 10 centers. Three hundred twenty-one patients were

12 Week Multicenter Clinical Study

35 (11.9) 27 (9.2) 19 (8.7)

N = 219

(161 patients).

index were randomized into groups of equal size to receive either EUFLEXXA (160 patients) or the active control

The clinical investigation was a prospective randomized, double-blinded, active control (commercially available

26 Week Multicenter Study

20 serious TEAEs were reported in 19 (3.2%) subjects during the study: 10 (3.4%) subjects in the

Tenderness 1 0

Baker's cyst 0 1

Arthralgia 11 9

Pain in extremity 13 (2.2) 10 (3.4) 3 (1.0) 3 (1.4)

Twelve (2.8%) subjects reported 20 serious TEAEs during the extension phase. Six of these subjects had received

Twenty-three serious TEAEs were reported in 19 (3.2%) subjects during the study: 10 (3.4%) subjects in the

Arthralgia 62 (10.5)

Tendonitis 3 (1.88) 2 (1.24)

Nervous system disorders

Headache 1 (0.63) 3 (1.86)

Gastrointestinal disorders

Nausea 3 (1.88)   0

Infections and infestations

Bronchitis 1 (0.63) 2 (1.24)

Musculoskeletal, connective tissue and bone

Joint swelling 3 (1.88) 3 (1.86)

Joint disorder 2 (1.25) 2 (1.24)

Tendonitis 3 (1.88) 2 (1.24)

System Organ Class Preferred Term

N = 219 (161 patients).

In the clinical studies, the overall incidence of adverse events was similar for both EUFLEXXA and saline injections.

The following is a list of adverse effects that can occur with either EUFLEXXA

Injury 17 (2.9) 9 (3.1) 8 (2.7) 9 (4.1)

Sinusitis 16 (2.7) 10 (3.4) 6 (2.0) 5 (2.3)

 homeowners. In several cases, the relationship to the study drug or saline injection was not established. The

Back pain 23 (3.9) 11 (3.7) 12 (4.1) 6 (2.7)

Pain in extremity 13 (2.2) 10 (3.4) 3 (1.0) 3 (1.4)

The following is a list of adverse events that can occur with either EUFLEXXA

injection, and the evaluable population, (i.e., those subjects who had average pain scores of 41-80

average of the five patient’s self-evaluation pain parameters measured by the VAS WOMAC index at Week

At the end of the core study, patients who continued to meet the inclusion criteria were randomized into the

of all subjects). Thirty (5.1%) subjects experienced severe TEAEs, and the proportion with severe events was

Most adverse events were mild or moderate in intensity. There were no deaths reported during the clinical

improvement in function lasting up to 6 months.

or prolonged (i.e., more than 1 hour) weight-bearing activities such as jogging or tennis within 48 hours

It is not recommended that patients receive simultaneous treatment with other non-steroidal anti-inflammatories, or use joints other

Water for injection q.s.

Disodium hydrogen phosphate dodecahydrate 0.56 mg

Sodium chloride 8.5 mg

benzalkonium chloride. Do not use disinfectants for skin preparation that contain quaternary ammonium

EUFLEXXA should not be administered through a needle previously used with medical solutions containing

EUFLEXXA contains:

19 mg sodium benzoate

9 mg chlorobutanol

19 mg sodium bicarbonate

6 mg benzyl alcohol

EUFLEXXA is prepared from purified hyaluronan (pronounced hye-ah-loo-ROE-nan). Hyaluronan is a

edema, unusual growth in size or shape of a foot, knee, leg, or hand, or joint swelling (less than 0.5"

itself is not a defense to a suit for specific performance or injunctive relief. The refusal or inability of a

In the 6-month extension phase, 66% of patients had not received a second injection of EUFLEXXA.

inflammation or infection, or a lump in the skin, do not receive EUFLEXXA.

Infection of the tract or the surrounding area can result in a localized infection, usually back pain or swelling near

Inflammation of the knee, fluid accumulation in the knee, or joint effusion (less than 0.5"

as a result of injection, is not a defense to a suit for specific performance or injunctive relief. The refusal or

The following is a list of severe adverse events reported by >1% of patients.

Table 1. Incidence of Adverse Events Reported by >1% of Patients

Table 2. Adherence of Adverse Events That Are Not Related to the Tracked Injection

Table 3. Incidence of Adverse Events Reported by >1% of Patients

Table 4. Study Data for EUFLEXXA Treated Groups by Adherence to Treatments with an incidence of 1 or Not Treatments Groups (95% Confidence Interval)

Table 5. Clinical Characteristics of Subjects Who Experienced Adverse Events of Interest
WHAT SHOULD I DO AFTER RECEIVING A EUFLEXXA INJECTION?

- Avoid physical activity for 4 hours following the injection to keep the knee from swelling.
- Avoid sitting or standing for 20 to 30 minutes after the injection.
- If you had a knee surgery, perform the range of motion exercises prescribed by your doctor immediately.

WHEN SHOULD I CALL MY DOCTOR (TROUBLESHOOTING)?

- If you have severe pain, nausea, fever, or any other symptoms that are not expected or unusual.
- If you have any other concerns or questions.

WHAT Kind OF MEDICATIONS SHOULD I AVOID?

- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen.
- Other knee pain medications.

HOW MANY INTRAARTICULAR TREATMENTS ARE AVAILABLE FOR DIABETES?

- EUFLEXXA is available for use in patients with diabetes.
- Additional treatments may be considered for patients requiring more than one treatment.

WHAT ARE THE CLINICAL STUDIES WITH EUFLEXXA?

- A dosage of 2 ml is injected intra-articularly into the affected knee at weekly intervals for three weeks.
- EUFLEXXA group improved 25.7 mm from the baseline pain score, compared to saline injection: Patients were asked to rate how pain was felt on a scale of 0 to 100, with 0 being no pain and 100 being worst possible pain.
- EUFLEXXA therapy lasting up to 6 months. The study also showed that EUFLEXXA has not been proven to relieve pain in any other joints.
- The pain scores were used to compare the effectiveness of EUFLEXXA with saline injection: Patients were asked to rate how pain was felt on a scale of 0 to 100, with 0 being no pain and 100 being worst possible pain.

WHEN SHOULD I CALL MY DOCTOR? (TROUBLESHOOTING)

- Stiffness, swelling or warmth in or around the knee
- Increased pain in the knee
- Difficulty starting to move after sitting for more than 30 minutes
- Pain that does not improve after 2 weeks
- Pain that makes it difficult to walk, climb stairs, or get up after sitting for a long time
- Pain that causes you to limp
- Pain that affects your ability to perform daily activities

WHEN SHOULD I CALL MY DOCTOR (TROUBLESHOOTING)?

- If you have any questions or problems, talk to your doctor. If you would like more information, please call 1-888-337-7464 toll-free or visit www.euflexxa.com.

TAKING EUFLEXXA WITH OTHER MEDICATIONS

- EUFLEXXA has been studied in combination with non-steroidal anti-inflammatory agents (NSAIDs) such as acetaminophen tablets used per week or in the proportion of subjects who were pain free at Week 26 or last observed in the study.
- EUFLEXXA is a registered trademark of Ferring BV
- EUFLEXXA is supplied in 2.25 mL nominal volume, disposable, pre-filled glass syringes containing 2 mL of clear, colorless, sterile solution.
- EUFLEXXA is a registered trademark of Ferring BV
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

CARE OF THE SYRINGE

- EUFLEXXA is supplied in 2.25 mL nominal volume, disposable, pre-filled glass syringes containing 2 mL of clear, colorless, sterile solution.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

INTERACTIONS

- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

ADMINISTRATION

- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

TREATMENT FAILURE

- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

SECONDARY ENDPOINTS

- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

SUGGESTED READING

- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

MANUFACTURED FOR

- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.
- EUFLEXXA is supplied in a blister pack for single use only.

Euflexxa PI_6309501103_Rev. 07/2016_R4         1/27/2017